Laurent Poulain Selected Research

ABT-737

1/2022	A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
1/2020	Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib.
1/2017	The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
3/2015	Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
2/2015	First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies.
6/2014	PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
6/2013	Sensitization of ovarian carcinoma cells to Bcl-xL-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family.
4/2013	Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laurent Poulain Research Topics

Disease

33	Neoplasms (Cancer) 05/2022 - 04/2002
23	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2002
22	Carcinoma (Carcinomatosis) 01/2020 - 01/2002
5	Mesothelioma 02/2015 - 04/2009
3	Adenocarcinoma 05/2022 - 01/2008
3	Testicular Neoplasms (Testicular Cancer) 02/2011 - 09/2008
3	Embryonal Carcinoma 02/2011 - 03/2009
3	Malignant Mesothelioma 06/2010 - 04/2009
2	Stomach Neoplasms (Stomach Cancer) 05/2022 - 03/2011
2	Chondrosarcoma 03/2022 - 05/2021
2	Ovarian Epithelial Carcinoma 01/2022 - 02/2021
2	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 07/2020 - 01/2020
2	Prostatic Neoplasms (Prostate Cancer) 07/2020 - 01/2020
2	Hypoxia (Hypoxemia) 02/2015 - 09/2012
1	Lymphoma (Lymphomas) 03/2022
1	Sarcoma (Soft Tissue Sarcoma) 03/2022
1	Osteosarcoma (Osteogenic Sarcoma) 03/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Thyroid Neoplasms (Thyroid Cancer) 11/2021
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/2021
1	Leukemia 01/2021
1	Peritoneal Neoplasms 10/2017
1	Ascites 01/2017
1	Carcinogenesis 04/2015
1	Burns 01/2012

Drug/Important Bio-Agent (IBA)

13	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 01/2002
8	ABT-737IBA 01/2022 - 04/2013
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2009
6	MicroRNAs (MicroRNA)IBA 03/2022 - 02/2011
6	PlatinumIBA 01/2022 - 06/2010
5	Apoptosis Regulatory ProteinsIBA 01/2022 - 04/2013
4	Biological ProductsIBA 10/2021 - 04/2012
4	Pharmaceutical PreparationsIBA 02/2021 - 01/2002
4	Citric Acid (Citrate)FDA LinkGeneric 10/2013 - 04/2009
4	Glucose (Dextrose)FDA LinkGeneric 02/2012 - 09/2006
4	IntegrinsIBA 02/2011 - 01/2002
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 02/2021 - 01/2020
3	Adenosine Triphosphate (ATP)IBA 03/2011 - 04/2009
3	Integrin alphaVIBA 04/2010 - 01/2002
2	Fluorouracil (Carac)FDA LinkGeneric 05/2022 - 04/2002
2	LuciferasesIBA 05/2021 - 10/2017
2	naftopidilIBA 07/2020 - 01/2020
2	trametinibIBA 01/2020 - 01/2017
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 01/2017
2	Small Interfering RNA (siRNA)IBA 10/2017 - 02/2015
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 01/2013
2	bromopyruvateIBA 02/2012 - 04/2009
2	LipidsIBA 01/2012 - 03/2011
2	PhosphofructokinasesIBA 03/2011 - 04/2009
2	VitronectinIBA 04/2010 - 01/2008
1	Leucovorin (Folinic Acid)FDA Link 05/2022
1	AntibodiesIBA 05/2022
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 05/2022
1	Docetaxel (Taxotere)FDA Link 05/2022
1	spartalizumabIBA 05/2022
1	bcl-2 Homologous Antagonist-Killer Protein (bcl 2 Homologous Antagonist Killer Protein)IBA 03/2022
1	folfirinoxIBA 01/2022
1	navitoclaxIBA 01/2022
1	Long Noncoding RNAIBA 12/2021
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2021
1	AntigensIBA 11/2021
1	RNA (Ribonucleic Acid)IBA 08/2021
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 02/2021
1	SaltsIBA 01/2020
1	Taxoids (Taxanes)IBA 01/2020
1	carboxyamido-triazole (carboxyamidotriazole)IBA 09/2018
1	atelocollagenIBA 10/2017
1	(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA 01/2017
1	Bcl-2-Like Protein 11IBA 01/2017
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2017
1	CalciumIBA 04/2015
1	Carboplatin (JM8)FDA LinkGeneric 03/2015
1	Caspase 3 (Caspase-3)IBA 03/2015
1	pyridoclaxIBA 02/2015
1	CollagenIBA 02/2015
1	High-Temperature Requirement A Serine Peptidase 1IBA 02/2015
1	Collagen Type I (Type I Collagen)IBA 02/2015
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 02/2015
1	dactolisibIBA 06/2014
1	3- (3- hydroxy- 4- methoxyphenyl)- 8H- thieno(2,3- b)pyrrolizin- 8- oneIBA 06/2013
1	Platinum Compounds (Compounds, Platinum)IBA 04/2013
1	Carrier Proteins (Binding Protein)IBA 01/2013
1	Peptide Initiation Factors (Initiation Factor)IBA 01/2013
1	Excipients (Suspending Agents)IBA 01/2013
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2013
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2013
1	TOR Serine-Threonine KinasesIBA 01/2013
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2012
1	Lactic Acid (Lactate)FDA LinkGeneric 02/2012
1	Oxygen (Dioxygen)IBA 02/2012
1	NucleotidesIBA 03/2011
1	cyclo(arginylglycyl)IBA 02/2011

Therapy/Procedure

14	Drug Therapy (Chemotherapy) 05/2022 - 03/2009
8	Therapeutics 02/2021 - 04/2009
2	Precision Medicine 02/2021 - 01/2017
2	Aftercare (After-Treatment) 04/2012 - 02/2011
1	Immunotherapy 05/2022
1	Neoadjuvant Therapy 05/2022
1	Transcutaneous Electric Nerve Stimulation (TENS) 01/2020
1	Withholding Treatment 01/2013